|
December 27, 2005 Categories: Uncategorized Posted by admin
Boston Scientific Corp. and Johnson & Johnson are mining U.S. product safety reports as a new marketing weapon in their battle over the $5 billion-a-year drug-coated heart stent business.
In comments to reporters last month, J&J cited so-called “adverse event” filings to argue that its Cypher stent caused fewer injuries during implantation than Boston Scientific’s Taxus. Boston Scientific answered that the same U.S. Food and Drug Administration database linked the Taxus to 28 percent fewer deaths than the Cypher.
Full News
|
|
